New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose
Your daily dose of the clinical news you may have missed.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity
This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.
Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair
Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.
Crinecerfont for Congenital Adrenal Hyperplasia Now Commercially Available, Neurocrine Biosciences Announces
The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.
CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected
The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.
